Target
CDK 6
3 abstracts
Abstract
LITESPARK-024: Randomized phase 1/2 study of belzutifan with or without palbociclib for treatment of advanced renal cell carcinoma (RCC).Org: Beth Israel Deaconess Medical Center, Rambam Health Care Campus, Huntsman Cancer Institute, Georgetown Lombardi Comprehensive Cancer Center, Merck & Co., Inc.,
Abstract
Outcome of second-line treatment after CDK4/6 inhibitors in hormonal-positive HER-2 negative metastatic breast cancer: Single institution experience.Org: King Abdulla Medical City/Makkah, Oncology Center, Medica Sur Hospital, King Abdullah Medical City, Mansoura University, Medical Oncology Department, Presidio Ospedaliero Santa Maria della Misericordia, Azienda Sanitaria Universitaria Friuli Centrale (ASUFC), Udine, Italy,
Abstract
A phase 2 basket trial of an ERK1/2 inhibitor (LY3214996) in combination with abemaciclib for patients whose tumors harbor pathogenic alterations in BRAF, RAF1, MAP2K1/2 ERK1/2, and NF1.Org: Division of Hematology and Oncology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan, Indiana University Simon Cancer Center and Roudebush VAMC, Department of Hematology/Oncology, IU Simon Comprehensive Cancer Center, Melvin and Bren Simon Cancer Center, Indianapolis, IN,